Obstetrics
 News
 Agenda
 Documents

 
 SUGAR-DIP
 
 2Close
 
 APRIL
 Highlow
 NethOSS
 
 PC
 Quadruple P
 
 SIMPLE III
 
 Stop or Go?
 
 STRIDER
 
 KEUZEHULP IMPLEMENTATIE
 
 INDEX
 MOTHER
 Ppromexil-III
 ALLO
 AMPHIA
 APOSTEL-I
 APOSTEL-II
 APOSTEL-III
 APOSTEL-IV
 
 Apostel VI
 ASB
 CHIPS
 DIGITAT
 ECV Implementation
 EuFis
 Fluxim
 GlucoMOMS
 HTA Longterm conseq.
 HTA Preference study
 HYPITAT
 HYPITAT-II
 HyRAS (Hypitat followup)
 Implementatie Tour
 IUPC
 PIMPP
 PPROMCerclage
 > PPROMEXIL
 PreCare
 PROBAAT
 PROBAAT-II
 PROBAAT-S
 ProTWIN
 SimpleII
 STAN
 TeMpOH-1
 TeMpOH-3
 TOSTI
 TOTEM
 Triple P
 TRUFFLE
 WOMB study

 ABCD-study
 CAMPUR
 Cancer in pregnancy
 HP4ALL-PC
 HP4ALL-RS
 IMPACT
 INCAS
 IRIS
 OOPUS
 STAN followup
 VIS-project
 ZAHARA II
 BIG CHANGE
 Doula study
 ECV tocolysis
 ECV Uterine relaxation
 EuroHeartSurvey
 FRUIT
 Keizerlijk litteken
 MAKE
 PRELHUDE
 PROMISES
 RAVEL
 SIMPLE
 VET study
 Wat bevalt beter
 ZAHARA 3
 ZOBASII
 

 

PPROMEXIL

 

Inleiden van de bevalling versus afwachten bij vrouwen met vroegtijdig gebroken vliezen tussen 34 en 37 weken zwangerschapsduur

Naar de
PPROMEXIL website

Problem:
Preterm pre labour rupture of the membranes (PPROM) is an importantclini-cal problem and a dilemma for the obstetric gynaecologist. On onehand, awaiting spontaneous labour may lead to an increase in infectiousdisease for both mother and child, whereas on the other hand inductionof labour leads to preterm birth with an increase in neonatal morbidity(e.g. respiratory dis-tress syndrome (RDS)) and a possible rise in thenumber of instrumental deliver-ies.

Objective:
To determine the effectiveness and cost-effectiveness of induction oflabour after PPROM between 34 and 37 weeks gestation compared toexpectant monitoring.

Study Design:
Multicentre prospective randomised controlled trial.

Study Population:
Pregnant women with preterm premature rupture of the membranes at a gestational age from 34 + 0/7 weeks until 37 weeks.

Interventions:
We will compare induction of labour with expectant monitoring.

Outcome measures:
Primary outcome is neonatal infection. Secondary outcome measures arematernal morbidity (chorioamnionitis, puerperal sepsis) and neonataldisease, instrumental delivery rate, quality of life and costs.

Power/Data Analyses:
We anticipate that a reduction of neonatal infection from 7.5% to 2.5%will outweigh the differences of an increase in RDS and additionalcosts due to admission of the child due to prematurity. Under theseassumptions, we will randomise 520 women (two groups of 260).

Economic Evaluation:
As we expect a reduction of infection in the intervention group, theeco-nomic analysis will be a cost-effectiveness analysis. Long termoutcomes will be evaluated using modelling.

Time Schedule:
Total study time 36months.

Projectleaders:
Dr. C. Willekes, azM, Maastricht
Dr. B.W. Mol, MMC, Veldhoven

Projectmembers:
Drs. D.P. van der Ham, VieCuri, Venlo
Drs. D. Bijlenga, AMC, Amsterdam
Drs. S.M.C. Vijgen, AMC, Amsterdam

ICT-support:
Mr. R. Scholte, AMC, Amsterdam

Subsidy:
ZonMw -
www.zonmw.nl